| 严绪华,梅格格,梅凌,等.基于网络药理学和分子对接的半枝莲二萜类化合物抗肝癌作用机制[J].安徽医药,2024,28(3):475-482. |
| 基于网络药理学和分子对接的半枝莲二萜类化合物抗肝癌作用机制 |
| Anti-hepatocellular carcinoma mechanism of diterpenoids of Scutellaria barbata on based on network pharmacology and molecular docking |
| |
| DOI：10.3969/j.issn.1009-6469.2024.03.010 |
| 中文关键词: 半枝莲 二萜类 肝癌 网络药理学 分子对接 作用机制 |
| 英文关键词: Barbated skullcup herb Diterpenes Liver cancer Network pharmacology Molecular docking Mechanism |
| 基金项目:武汉市卫生健康委医学科研项目( WZ20A08) |
|
| 摘要点击次数: 258 |
| 全文下载次数: 1429 |
| 中文摘要: |
| 目的基于网络药理学和分子对接技术探讨半枝莲二萜类成分抗肝癌的作用机制。方法根据文献调研( 1987年 1月至 2022年 7月)获得的 155个半枝莲二萜类化合物，通过 SwissADME平台筛选后得到符合条件的 93种活性成分，并通过 Swiss Target Prediction网络平台预测得到其中 65个化合物可能的作用靶点；通过 GeneCards、OMIM、PharmGkb、TTD、DrugBank以及 GEO、TCGA数据库获取与肝癌有关的靶点，利用 Cytoscape软件构建可视化“活性成分 -靶点 -肝癌”网络作用图，并通过度值筛选主要活性成分；使用 String平台进行蛋白质–蛋白质相互作用( PPI)网络功能富集分析，利用 Cytoscape软件构建 PPI可视化网络图，通过 cytoHubba插件的评分规则筛选出核心靶点和关键靶点；采用 R语言软件包对半枝莲二萜抗肝癌的作用靶点进行基因本体( GO)功能和京都基因和基因组数据库( KEGG)通路富集分析；使用 AutoDock vina软件对主要活性成分与关键靶点进行对接分析。结果筛选出半枝莲二萜中 6种活性成分包括 Scutebarbolide I、Scutebata O、Scutelinquanine D、Scutellone F、 Scutellone H和 Scutebarbatine J，预测得到 10个抗肝癌核心靶点，其中蛋白 STAT3、MAPK1、MAPK3、HSP90AA1、PIK3R1和 PIK3CA为关键靶点。基因富集分析得到 953个 GO功能条目和 137条通路( P<0.05)；分子对接结果显示，半枝莲二萜活性成分与关键靶点间存在潜在结合位点；网络药理学分析表明半枝莲二萜成分可能通过肽基 .丝氨酸磷酸化、肽基 .丝氨酸修饰、磷酸酶结合、蛋白质丝氨酸 /苏氨酸激酶活性等生物学过程，作用于 STAT3、MAPK1、MAPK3、PIK3R1、PIK3CA等关键蛋白的表达，进一步调控癌症中蛋白多糖、化学致癌受体激活、催乳素信号通路、癌症程序性死亡受体配体 1(PD-L1)表达和程序性死亡受体 1(PD-1)检查点通路等信号通路，发挥治疗肝癌作用。结论半枝莲二萜类化合物能够通过多分子、多靶点、多通路、多作用机制达到治疗肝癌作用。 |
| 英文摘要: |
| Objective To explore the potential mechanism of diterpenoids from Scutellaria barbata against liver cancer based on net. work pharmacology and molecular docking method.Methods According to literature investigation (January 1987 to July 2022), 155 diterpenoids of S. barbata were obtained, and 93 qualified active components were obtained after screening by Swiss ADME, of which65 compounds can predict their action targets on Swiss target prediction network platform; The targets related to liver cancer were ob.tained through GeneCards, OMIM, PharmGKB, TTD, DrugBank, GEO and TCGA databases. The network diagram of "active ingredienttarget disease" was constructed with the help of Cytoscape software, and the main active ingredients were screened through the degreevalue; Protein-protein interaction (PPI) analysis was carried out by String platform; PPI network diagram was made by Cytoscape soft.ware, and core targets and key targets were screened out through the score of cytohubba plug-in; The R package was used to analyze theGO function and KEGG pathway; Autodock Vina software was used for molecular docking between main active components and key tar.gets.Results Six active diterpenoids of S. barbata were screened, including scutebarbolide I, scutebata O, scutelinquanine D, Scutel. lone F, Scutellone H and Scutebarbaratine J. Ten core targets were predicted, including STAT3, MAPK1, MAPK3, HSP90AA1,PIK3R1 and PIK3CA are the key targets. A total of 953 GO items and 137 pathways were obtained by gene enrichment analysis (P < 0.05); The results of molecular docking showed that there were potential binding sites between the active diterpenoids of S. barbata and the key targets; Network pharmacological analysis shows that the diterpenoids of S. barbata played a role in the treatment of liver can.cer, which may act on the expression of key proteins such as STAT3, MAPK1 and MAPK3, through biological processes such as pep.tide-serine phosphorylation, peptide-serine modification, phosphatase binding and protein serine/threonine kinase activity, and furtherregulate the signal pathways such as proteoglycans in cancer, chemical carcinogen receptor activation, prolactin signaling pathway, andPD.L1 expression and PD.1 checkpoint pathway in cancer, et al.Conclusion The diterpenoids of S. barbata can treat liver cancer through multi molecules, multi-target, multi-channel and multi action mechanism. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
